We have a companion blog post for this episode - read it here

This episode explores how weight loss medications, specifically GLP-1 receptor agonists like Zepbound, are emerging as a game-changer for sleep apnea treatment, offering an alternative to traditional CPAP therapy. It highlights the significant economic and personal burden of untreated sleep apnea and emphasizes the direct correlation between weight loss and improved sleep apnea severity. Clinical trials demonstrate that these medications not only facilitate substantial weight loss but also lead to dramatic reductions in sleep apnea severity, with many patients experiencing remission or significant improvement. The recent FDA approval of Zepbound for sleep apnea is presented as a crucial development that could improve insurance coverage, making this innovative treatment more accessible to those struggling with the condition.